Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

BACKGROUND: Osimertinib—the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)—has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib demonstrated central nervous system activity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gen, Soei, Tanaka, Ichidai, Morise, Masahiro, Koyama, Junji, Kodama, Yuta, Matsui, Akira, Miyazawa, Ayako, Hase, Tetsunari, Hibino, Yoshitaka, Yokoyama, Toshihiko, Kimura, Tomoki, Yoshida, Norio, Sato, Mitsuo, Hashimoto, Naozumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195197/
https://www.ncbi.nlm.nih.gov/pubmed/35698083
http://dx.doi.org/10.1186/s12885-022-09741-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195197/
https://www.ncbi.nlm.nih.gov/pubmed/35698083
http://dx.doi.org/10.1186/s12885-022-09741-8

Ejemplares similares